Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Long-Term Investments: 2019-2024

Historic Long-Term Investments for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $80.7 million.

  • Allogene Therapeutics' Long-Term Investments fell 77.69% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year decrease of 77.69%. This contributed to the annual value of $80.7 million for FY2024, which is 2113.25% up from last year.
  • Latest data reveals that Allogene Therapeutics reported Long-Term Investments of $80.7 million as of FY2024, which was up 2,113.25% from $3.6 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Long-Term Investments registered a high of $352.2 million during FY2021, and its lowest value of $3.6 million during FY2023.
  • Over the past 3 years, Allogene Therapeutics' median Long-Term Investments value was $59.2 million (recorded in 2022), while the average stood at $47.8 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first plummeted by 93.84% in 2023, then surged by 2,113.25% in 2024.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Long-Term Investments stood at $204.2 million in 2020, then spiked by 72.46% to $352.2 million in 2021, then plummeted by 83.20% to $59.2 million in 2022, then plummeted by 93.84% to $3.6 million in 2023, then spiked by 2,113.25% to $80.7 million in 2024.